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http://dx.doi.org/10.1016/j.stemcr.2017.04.015SUMMARYClinical trials of stem cell therapy to treat ischemic heart disease primarily use heterogeneous stem cell populations. Small benefits occur
via paracrine mechanisms that include stimulating angiogenesis, and increased understanding of these mechanisms would help to
improve patient outcomes. Cardiosphere-derived-cells (CDCs) are an example of these heterogeneous stem cell populations, cultured
from cardiac tissue. CDCs express endoglin, a co-receptor that binds specific transforming growth factor b (TGFb) family ligands,
including bonemorphogenetic protein 9 (BMP9). In endothelial cells endoglin regulates angiogenic responses, andwe therefore hypoth-
esized that endoglin is required to promote the paracrine pro-angiogenic properties of CDCs. Cre/LoxP technologywas used to genetically
manipulate endoglin expression in CDCs, and we found that the pro-angiogenic properties of the CDC secretome are endoglin depen-
dent both in vitro and in vivo. Importantly, BMP9pre-treatment of endoglin-depletedCDCs restores their pro-angiogenic paracrine prop-
erties. As BMP9 signaling is normally required tomaintain endoglin expression, we propose thatmedia containing BMP9 could be critical
for therapeutic CDC preparation.INTRODUCTION
Stem cells have both differentiation capacities and para-
crine effects that can be harnessed to promote tissue regen-
eration. Over the last decade, a range of heterogeneous
stem cell populations including mesenchymal stem cells
(MSCs) and cardiac stem cells (CSCs) have been used in
clinical trials of autologous cell-based therapy to treat
ischemic heart disease (Madonna et al., 2016). Although
these cells show low engraftment and poor differentiation
abilities in vivo, there is a consensus that they are safe and
have the capacity to promote small improvements in heart
function primarily via paracrine mechanisms. However,
in all cases these mechanisms are poorly characterized.
Moving forward, if the nature of these paracrine mecha-
nisms can be better understood, the prospects of improving
their efficacy may be considerably increased. In particular,
improving their pro-angiogenic paracrine properties will
be critical for treating ischemic disease.
Cardiospheres (CSps) are one of these heterogeneous
stem cell populations, and form spontaneously from
cultured cardiac biopsies (Davis et al., 2009; Messina
et al., 2004). CSps comprise self-assembling stem cell clus-
ters with the potential to differentiate to myocardial cell
subtypes (Li et al., 2011; Smith et al., 2007). They have
been shown to promote cardiac repair following myocar-
dial infarction (MI) via paracrine mechanisms such as pro-
moting angiogenesis and cardiomyocyte proliferation in
the recipient tissue (Chimenti et al., 2010; Li et al., 2012).Stem Cell
This is an open access artiCSp cellular clusters are relatively large (>100 mm in diam-
eter) and intravascular delivery carries an inherent risk of
precipitating microthrombotic events. Therefore, much
of the work in this area has focused on cardiosphere-
derived cells (CDCs), which are suspensions of single cells
prepared from cultured CSps.
Both CSps and CDCs express endoglin (also known as
CD105), considered a characteristic cell-surface marker of
these cells (Smith et al., 2007). Endoglin is a membrane
co-receptor for specific members of the transforming
growth factor b (TGFb) family of cytokines that regulate
many aspects of cell function. In endothelial cells, endo-
glin promotes angiogenesis by regulating the balance of
TGFb signaling through ALK5 and ALK1 receptors, essen-
tially by enhancing signaling through ALK1 and reducing
signaling through ALK5 (Lebrin et al., 2004). Mice without
endoglin die in embryogenesis from angiogenic defects
while mice that are heterozygous for endoglin mutations
(Eng+/) show poor reperfusion in mouse models of
hindlimb ischemic injury (Jerkic et al., 2006; Seghers
et al., 2012). Furthermore, following MI, endogenous
levels of vascularity within the infarct border zone is
much lower in Eng+/ mice compared with wild-type con-
trols (van Laake et al., 2006). In addition to angiogenesis,
endoglin is also required for vessel integrity. Patients car-
rying deleteriousmutations in endoglin develop hereditary
hemorrhagic telangiectasia (McAllister et al., 1994), a dis-
ease typified by fragile bleeding vessels and arteriovenous
malformations (AVMs) (Shovlin, 2010). Consistent with aReports j Vol. 8 j 1287–1298 j May 9, 2017 j ª 2017 The Author(s). 1287
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Endoglin Is Expressed in CDCs
and Can Be Efficiently Depleted Using
Cre-LoxP Recombination
(A) Flow-cytometric analyses of murine
CDCs at passage 2. Summary of the per-
centage of CDCs expressing mesenchymal
(CD90, endoglin), hematopoietic (CD45),
and stem cell (cKit, Sca-1) markers from
three independent experiments and plotted
as mean percentage ± SEM.
(B) Summary of the floxed endoglin allele
(Engfl) and Cre recombination driven by the
R26-CreERT2 allele in the presence of 4-hy-
droxytamoxifen to generate a null endoglin
knockout (EngKO) allele.
(C) Immunostained CDCs showing that
transient 48-hr treatment with 4-hydrox-
ytamoxifen leads to efficient endoglin pro-
tein depletion. Scale bar, 50 mm.
(D) qPCR analysis showing loss of endoglin
transcripts in EngKO CDCs. ***p < 0.001.key role in endothelial cells, endothelial-specific loss of en-
doglin in early postnatal life leads to angiogenic defects
and AVMs (Arthur et al., 2000; Mahmoud et al., 2010).
Based on its role in endothelial cells, we hypothesized
that endoglin also has a pro-angiogenic role in CDCs,
contributing to their paracrine pro-angiogenic effects. To
address this question, we depleted endoglin from CDCs
using Cre-LoxP genetics in a mouse model, and tested
the corresponding effect on downstream angiogenesis re-
sponses in a wide range of in vitro and in vivo angiogenesis
assays as well as a mouse model of MI.RESULTS
Endoglin Is Required for CDC-Mediated
Pro-angiogenic Paracrine Effects
CDCs were characterized using fluorescence-activated
cell sorting (FACS) and immunocytostaining (Figure 1).
The majority of CDCs at passage 2 (P2) express endoglin,
although the proportion of endoglin-positive CDCs re-
duces at later passages (not shown). A significant propor-
tion (56%) of P2 CDCs also express CD90, while 4% of
CDCs express the stem cell marker Kit and 10% express
Ly6a (also known as Sca-1). Very few CDCs (2%) are
CD45+, confirming that they are not derived from hemato-
poietic cells. Mice carrying the CAG-eGFP transgene were
used to generate GFP-expressing CDCs that could be
tracked over time (Figure S1). To determine the role of en-
doglin, we prepared CDCs from mice in which Endoglin
can be depleted by Cre/LoxP technology. CDCs from
CAG-eGFP;Engfl/fl;Rosa26-CreERT2 mice were divided into1288 Stem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017two matched populations for each experiment. One
CDC population was used as a wild-type control and
the corresponding CDCs were transiently treated with
4-hydroxytamoxifen (4-OHT) to generate EngKOCDCs (Fig-
ure 1B). Endoglin loss was confirmed at the transcript and
protein level by qPCR and immunocytostaining, respec-
tively (Figures 1C and 1D). The paracrine pro-angiogenic
effects of the secretome of CDCs with and without endo-
glin were compared using conditioned medium (CM)
that had been harvested from P2 CDCs at equivalent cell
densities, and checked for equal protein concentration
prior to use (Figure S2A).
The pro-angiogenic effects of the secretomes from EngKO
and control CDCs were compared in a range of angiogen-
esis assays using both in vitro and in vivo conditions.
First, using the human microvascular endothelial cell 1
(HMEC-1) cell line in a 2D Matrigel angiogenesis assay,
we observed that control CDC-CM significantly enhanced
endothelial tubule formation compared with basal me-
dium. However, this pro-angiogenic effect of CDC-CM
was lost when CMwas prepared from EngKO CDCs (Figures
2A–2D). Similarly, using human umbilical vein endothelial
cells (HUVECs) in a spheroid angiogenesis assay, the pro-
angiogenic effect of CDC-CM was absent following endo-
glin depletion fromCDCs (Figures 2E–2H). Importantly, us-
ing CDCs cultured from C57BL/6 mice, we confirmed that
4-OHT treatment alone has no effect on the pro-angiogenic
properties of CDC-CM in this assay (data not shown). In
addition, a subdermal Matrigel plug assay was used to test
whether the pro-angiogenic paracrine effects of CDCs
were endoglin-dependent in vivo. In this assay, endothelial
cells form a functional vascular network in a subdermal
Figure 2. Endoglin Expression Is Required for Paracrine CDC-
Mediated Pro-angiogenic Effects In Vitro
(A–D) Representative phase-contrast micrographs showing the
relative pro-angiogenic effects of basal medium (IMDM, A), CDC-CM
(B), and EngKO CDC-CM (C) on HMEC tubule formation in a 2D Ma-
trigel assay. Quantitation of tubule length (D) shows that the pro-
angiogenic effect of CDC-CM is lost in the absence of endoglin. Data
are plotted as mean ± SEM from eight independent experiments;
*p < 0.05, **p < 0.01. Scale bar, 200 mm.
(E–H) Representative phase-contrast micrographs showing angio-
genic sprouting of HUVEC spheroids in the presence of basal me-
dium (E), control CM (F), or EngKO CM (G). Angiogenesis promoted
by control CM is lost in EngKO CM (H). Data from three independent
experiments with 20 spheroids per group are shown as mean ± SEM;
*p < 0.05. Scale bar, 100 mm.Matrigel plug over a 2-week time course. Matrigel plugs
seeded with CM from EngKO CDCs showed significantly
reduced vessel formation compared with CM from control
CDCs (Figures 3A–3F). In addition, endothelial cell prolifer-
ation was reduced in plugs seeded with CM from EngKO
CDCs comparedwith control CM (Figures 3G–3I), confirm-
ing that endoglin was required for the pro-proliferativeparacrine effects of CDCs in vivo. Furthermore, we
observed reduced numbers of mature muscularized vessels
in Matrigel plugs containing EngKO CDC-CM compared
with control CDC-CM, indicating that the pro-angiogenic
effect of CDC-CM was of lasting duration that led to
mature muscularized vessels, and that this was also endo-
glin dependent (Figure 3F).
Endoglin Is Required for CDC-Mediated
Pro-angiogenic Effects after Myocardial Infarction
To determine whether the pro-angiogenic effect of CDCs
following MI was also endoglin dependent, we subjected
male C57BL/6 mice to a surgical MI and injected CDCs
into the infarct border zone. All CDCs were prepared
from CAG-eGFP;Engfl/fl;Rosa26-CreERT2 permitting genera-
tion of matched control and EngKO CDCs, and intracardiac
injections were performed by a surgeon blinded to CDC
genotype. Hearts were harvested after 4 weeks to evaluate
stable vascularity in the infarct border zone. Delivery of
control CDCs significantly increased the vascularity of
the infarct border zone, consistent with the reported para-
crine pro-angiogenic effect of CDCs in vivo (Chimenti
et al., 2010). However, endoglin-depleted CDCs had little
benefit, generating significantly reduced vessel density
in the infarct border zone compared with hearts injected
with control CDCs (Figures 4A–4E). These findings were
consistent with our earlier data showing that the pro-
angiogenic effect of CDCs was endoglin dependent.
In addition, any direct contribution of CDCs from CAG-
eGFP donor mice to the vessels of the wild-type recipient
hearts was investigated using anti-GFP immunostaining.
Direct contribution of GFP-labeled CDCs to these vessels
was rarely observed, confirming the pro-angiogenic effect
of CDCs were a result of paracrine mechanisms (Figures
S2B and S2C).
Heart function was measured using cardiac magnetic
resonance imaging (MRI) at 1 week and again at 4 weeks
following MI, but the pro-angiogenic effect of CDCs was
insufficient to promote significant rescue of cardiac func-
tion, in line with the large infarct size used in this study
(Figure S3). Left ventricular mass, ejection fraction, and
end-diastolic and systolic volumes at 1 week and at 4 weeks
following MI were similar in both CDC-treated and CDC-
untreated mice, irrespective of the presence of endoglin
(Figure S3).
As endoglin acts as a co-receptor for bone morphoge-
netic protein 9 (BMP9), BMP10, TGFb1, and TGFb3 ligands
(Castonguay et al., 2011; Cheifetz et al., 1992; Scharpfe-
necker et al., 2007), we used a separate group of wild-type
C57BL/6 mice (without CDCs) to examine the relative
levels of these ligands in infarcted myocardium, as well as
in serum, during the first week after MI. This time period
was chosen as it corresponds to the period immediatelyStem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017 1289
Figure 3. Endoglin Expression Is Required for Paracrine CDC-
Mediated Pro-angiogenic Effects in 3D Matrigel Plugs In Vivo
(A and B) Whole-mount view of freshly dissected Matrigel plugs at
14 days after seeding with MLECs and either CM (A) or EngKO CM (B)
shows decreased vascularity of EngKO CM plugs. Scale bar, 3 mm.
(C–F) Cryosections of Matrigel plug immunostained with anti-
CD31to detect endothelial cells (green) and anti-SM22a to detect
vascular smooth muscle cells (red) shows decreased vascularity of
Matrigel plugs containing EngKO CM (D) compared with CM (C). Scale
bar, 100 mm. Quantification of CD31 (E) and SM22a (F) staining in
six Matrigel plugs per group using ImageJ. *p < 0.05, ***p < 0.001.
(G–I) Matrigel plug sections immunostained with anti-phospho-
histone-3 Ser10 (pH3) to detect proliferating cells (green) and
anti-CD31 to detect endothelial cells (red) shows proliferating
endothelial cells (arrows, G). There are fewer proliferating endo-
thelial cells in plugs containing EngKO CM (H) compared with
1290 Stem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017after CDC injection, when the ligands would be available
to interact with endoglin-expressing CDCs, before CDCs
are cleared from the recipient heart tissue. Neither BMP9
nor BMP10 were detected by qPCR in the left ventricular
tissue either before or after MI (data not shown). In
contrast, qPCR revealed dynamic changes in expression
of TGFb1 and TGFb3 in the left ventricular tissue following
MI, reaching a peak at day 5 for TGFb1 and at day 7 for
TGFb3 (Figure S4), similar to previously published data
(Christia et al., 2013; Deten et al., 2001). In addition,
TGFb1, BMP9, and BMP10 ligands are present in serum
throughout this period, both in MI and sham groups.
Circulating TGFb1 protein levels remain unchanged, but
BMP9 concentrations significantly decrease and BMP10
concentrations significantly increase in the days following
surgery (Figure S4). TGFb3 protein was not detectable
in serum from any of the mice (data not shown). The
availability of TGFb1, BMP9, and BMP10 protein in serum
and increased TGFb1 and TGFb3 expression in infarcted
myocardium means that the presence of endoglin in
CDCs is biologically relevant during the cardiac healing
process.
Endoglin Is Required for CDC-CM to Promote
Endothelial Cell Migration but Does Not Affect VEGF
Signaling
As endoglin was required for the pro-angiogenic effects
of CDCs, we next sought to investigate the mechanism.
Vascular endothelial growth factor A (VEGFA) is the ‘‘mas-
ter’’ pro-angiogenic factor, and crosstalk occurs between
endoglin and VEGF pathways (Liu et al., 2014). Therefore,
altered VEGF signaling could potentially explain the
reduced angiogenic response seen in EngKO CDC-CM.
However, we observed no difference in VEGFA content of
CM from control or EngKO CDCs (Figure S5). Furthermore,
HUVECs treated with control CM and EngKO CM showed
similar phospho-AKT and phospho-GSK responses (Fig-
ure S5), consistent with comparable signaling responses
to VEGF. As angiogenesis results from increased prolifera-
tion and migration of endothelial cells, we next tested
the effect of CDC-CM on these endothelial responses.
There was a small decrease in HUVEC proliferation in the
presence of EngKO CDC-CM compared with control CDC-
CM (Figures 5A and 5B), but no change in HUVEC viability
in the presence of control or EngKO CDC-CM (Figures 5C
and 5D). However, ‘‘scratch-wound’’ closure was signifi-
cantly slower in the presence of EngKO CDC-CM compared
with control CDC-CM (Figures 5E and 5F), consistent withCM (G). Nuclei of all cells are counterstained with DAPI (blue) Scale
bar, 20 mm. Data are quantified as percentage proliferating endo-
thelial cells (I); n = 6 Matrigel plugs per group; *p < 0.05.
Figure 4. Endoglin Is Required for CDC-Mediated Pro-angio-
genic Effects in the Infarct Border Zone of the Heart after
Myocardial Infarction
(A–E) Vessel density in the border zone of MI hearts was analyzed
using CD31 immunostaining at 4 weeks post injury in mice that had
sham operation (A), MI with PBS injection (B), MI with CDC in-
jection (C), and MI with EngKO CDC injection (D). Scale bar, 50 mm.
Area of CD31 immunofluorescence was quantified in 20 fields of
view per heart and analyzed with ImageJ software. n = 5 sham, n = 8
MI + PBS, n = 8 MI + CDC, and n = 7 MI + EngKO CDC; *p < 0.05.a reduced pro-migratory effect of EngKO CDC-CM. Taken
together, this evidence points to the requirement of
endoglin in CDCs to promote the pro-proliferative and
pro-migratory paracrine effects of CDC-CM on endothelial
cells.
Endoglin-Dependent Expression of Pro- and
Anti-angiogenic Factors in the CDC Secretome
Endoglin promotes signaling through ALK1 and reduces
signaling through ALK5 in endothelial cells to promoteangiogenesis (Figure 6A) (Lebrin et al., 2004). Also, CDCs
express the receptor profile required for activation of
both ALK1 and ALK5 pathways (Figure S6). Therefore, we
sought to determine whether loss of endoglin in CDCs
altered the balance of TGFb/BMP signaling through
SMAD1/5/8 (ALK1 pathway) or through SMAD2/3 (ALK5
pathway) and whether this could explain the altered pro-
angiogenic properties of the CDC secretome. Endoglin-
deficient and control CDCs showed no detectable differ-
ence in phosphorylation of SMAD2 or SMAD3 either in
response to basal medium alone or following TGFb stimu-
lation (Figures 6B and 6C). However, endoglin-deficient
CDCs did show significantly reduced phosphorylation
of SMAD1/5/8 compared with control CDCs, which was
partially rescued in response to BMP9 stimulation (Fig-
ure 6D). Therefore, the loss of pro-angiogenic effects in
CM from endoglin-depleted CDCs could be a consequence
of reduced BMP9 signaling or an altered balance of ALK5/
ALK1 signaling. To test whether reduced BMP9 signaling
was responsible for the loss of the pro-angiogenic proper-
ties of EngKO CM, we pre-treated CDCs (with and without
endoglin depletion) with BMP9 ligand. In parallel, to deter-
mine whether the defective pro-angiogenic properties
of EngKO CDCs were due to relative overactivity of the
ALK5 signaling pathway, we treated EngKO CDCs with
ALK5 inhibitor (SB431542). CDC-CM was harvested as
before, and CM-induced angiogenic outcomes were tested
using the spheroid angiogenesis assay and endothelial
migration tested using the scratch-wound healing assay.
Pre-treatment of CDCs with ALK5 inhibitor did not rescue
the reduced pro-angiogenic or pro-migratory effects of
EngKO CDC-CM. However, pre-treatment of CDCs with
BMP9 did restore the pro-angiogenic and pro-migratory ef-
fects of EngKO CDC-CM to those of control CDC-CM (Fig-
ure 7). These findings show that endoglin protein responds
to local levels of BMP9, and is responsible for promoting
CDC-mediated pro-angiogenic paracrine effects, as sum-
marized schematically in Figure S7.DISCUSSION
The paracrine beneficial mechanisms of heterogeneous
stem cell populations such as CDCs are poorly understood.
Our data show that Endoglin is essential for paracrine-
mediated angiogenesis by CDCs. The CDC secretome
promotes an endoglin-dependent increase in endothelial
tubule formation and endothelial cell migration in vitro,
as well as an increased endothelial cell proliferation and
higher density of mature blood vessels in vivo. Thus, the
endoglin-dependent pro-angiogenic effects of CDC-CM
are consistent across a wide range of in vitro and in vivo
angiogenesis assays.Stem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017 1291
Figure 5. Endoglin Is Required to Maxi-
mize Pro-proliferative and Pro-migratory
Endothelial Cell Responses
(A and B) Proliferation of HUVECs measured
using a fluorometric assay (CyQUANT) at
24 hr (A) and 48 hr (B) is reduced in
the presence of EngKO CM compared with
control CM. Data from nine independent
experiments are represented as mean ±
SEM; *p < 0.05.
(C and D) Viability of HUVECs was measured
using a colorimetric (MTT) assay and is
similar following treatment with control CM
or EngKO CM for 24 hr (C) and 48 hr (D). Data
from seven independent experiments are
represented as mean ± SEM.
(E and F) HUVEC migration in the scratch-
wound assay is significantly reduced in
the presence of EngKO CM compared with
control CM. Data from five independent
experiments are plotted as mean ± SEM,
**p < 0.01.Endoglin is a recognized surface marker of CDCs and
is also considered one of the minimal criteria for MSCs
(Dominici et al., 2006). Thus, it is relevant to our findings
that human MSCs from umbilical cord blood, which
have been enriched for endoglin-expressing cells, lead to
an increase in capillary density following delivery to a
mouse MI model (Gaebel et al., 2011). We found that
loss of endoglin expression in CDCs leads to reduced
BMP9-dependent SMAD1/5/8 signaling responses in the
CDCs, and reduced the pro-angiogenic properties of the
secretome. Treatment of endoglin-deficient CDCs with
BMP9 significantly increased the pSMAD1/5/8 activation
response and rescued the pro-angiogenic defects of the
secretome. In contrast, pre-treatment with the ALK5 inhib-
itor SB431542 did not rescue the angiogenic defects of
EngKO CM, suggesting that relative overactivity of the
ALK5 pathway over the ALK1 pathway following endoglin
depletion did not contribute to the angiogenic defects
(Figure S7). However, this is a little more complex to inter-1292 Stem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017pret, as ALK5 is also required for TGFb signaling through
the ALK1 pathway (Goumans et al., 2003). Neverthe-
less, taken together the data indicate BMP9-dependent
SMAD1/5/8 signaling as a critical pathway downstream of
endoglin that leads to the production of a pro-angiogenic
CDC secretome.
In the heart itself we observed that increased levels
of TGFb1 and TGFb3 are endogenously produced in the
days immediately following MI, in agreement with previ-
ous data (Christia et al., 2013; Deten et al., 2001). In addi-
tion, we show that TGFb1, BMP9, and BMP10 proteins
are all present in the circulation followingMI. Each of these
ligands are known to interact with endoglin to promote
downstream SMAD1/5/8 signaling (Castonguay et al.,
2011; Lebrin et al., 2004) and can therefore interact with
endoglin present on the surface of CDCs immediately
following injection to the infarct border zone, thereby
influencing the production of downstream paracrine fac-
tors by CDCs.
Figure 6. Endoglin-Deficient CDCs Show
Reduced Endogenous SMAD1/5/8 Acti-
vation that Can Be Rescued by BMP9
Treatment
(A) Summary of TGFb and BMP9 signaling
pathways. TGFb/ALK5 and BMP9/ALK1
signaling are propagated through phos-
phorylation of SMAD2/3 and SMAD1/5/8,
respectively. TGFb generally signals via a
complex of TGFBR2 and ALK5 (upper left)
while BMP9 (and BMP10) signals via a
complex of BMPR2 and ALK1 (upper right).
Endoglin acts as a co-receptor to promote
BMP9/10 signaling through the ALK1 re-
ceptor complex, although it can also pro-
mote TGFb signaling through ALK1 to acti-
vate SMAD1/5/8 (not shown).
(B and C) Representative western blots
show that baseline and TGFb1-induced
SMAD2 phosphorylation (B) and SMAD3
phosphorylation (C) are similar in control
and in EngKO CDCs. Densitometric analysis
of pSMAD2 and pSMAD3 band intensity
relative to a-tubulin are shown as mean ±
SEM from three independent experiments.
*p < 0.05; **p < 0.01.
(D) Representative western blot shows
SMAD1/5/8 phosphorylation is reduced in
EngKO CDCs and this is partially rescued
following treatment with 2 ng/mL BMP9 for
30 min. Densitometric analysis of pSMAD1/
5/8 band intensity relative to a-tubulin is
shown as mean ± SEM from five indepen-
dent experiments; *p < 0.05.BMP9 and BMP10 have a particularly high affinity for
endoglin, and BMP9 is found in an active form in the
circulation (Bidart et al., 2012). Furthermore, we and others
have previously shown that BMP9 signaling through ALK1
is required to maintain endoglin expression (Morikawa
et al., 2011; Tual-Chalot et al., 2014). Therefore, endoglin
expression on CDCs is required for normal BMP9 signaling
responses, and availability of BMP9 in themedia is required
tomaintain endoglin expression. As Endoglin is essential to
generate the pro-angiogenic paracrine properties of CDCs,
active BMP9 that is normally present in culture serum will
be important to maintain endoglin expression during
culture and expansion of CDCs (and MSCs) for clinical
use. Indeed, reduced endoglin expressionhas been reported
when MSCs are cultured in serum-free conditions (Mark
et al., 2013). This is a critical factor to consider in the prep-
aration of stemcell populations for pro-angiogenic therapy.
Recentwork has shown that endoglin plays an additional
role in the later stages of cardiac healing during formation
of the collagenous scar tissue (Tseliou et al., 2014). Endo-
glin can be cleaved from the cell surface by metallopro-teases such as MMP14 (Hawinkels et al., 2010). Soluble
endoglin, shed from the surface of CSps, leads to reduced
fibrosis whenCSps are delivered in the chronic repair phase
(1month postMI) in a ratmodel ofMI (Tseliou et al., 2014).
However, Endoglin can also play a detrimental role in
fibrosis. It is expressed in myofibroblasts, and reduced
endoglin levels protect against adverse fibrotic responses
in the aortic constriction model of hypertension (Kapur
et al., 2012). Thus, in addition to its pro-angiogenic roles
in the acute setting of MI, endoglin can also influence later
fibrosis outcomes.
Although CDCs clearly led to a higher capillary density
in the infarct border zone, we found no CDC-mediated
improvement in ejection fraction or adverse left ventricular
remodeling. Thus increased angiogenesis alone is insuffi-
cient to improve cardiac function in a large permanent
infarct, where almost all the left ventricular free wall is
affected and ultimately replaced by scar tissue. In this study
great care was taken to minimize variation in infarct size,
due to its major impact on outcomes (Redgrave et al.,
2016). Furthermore, cardiac MRI was used to provide aStem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017 1293
Figure 7. Pre-treatment of CDCs with BMP9 Rescues the Para-
crine Pro-angiogenic Defects Caused by Endoglin Depletion
(A) EngKO CM shows reduced pro-angiogenic effects compared with
CM from control CDCs in the HUVEC spheroid assay. Pre-treatment
of CDCs with 2 ng/mL of BMP9 for 24 hr prior to generating CM led
to rescue of the EngKO CM pro-angiogenic defect. In contrast, pre-
treatment with ALK5 inhibitor (SB431542) had no effect on the
EngKO CM pro-angiogenic defect. Data are plotted as mean ± SEM
from three independent experiments; ***p < 0.001.
(B) Healing of the HUVEC scratch-wound assay is reduced in the
presence of EngKO CM. CM collected after pre-treatment of EngKO
CDCs with 2 ng/mL BMP9 for 24 hr restored the pro-migratory ca-
pacity of EngKO CM. In contrast, pre-treatment with ALK5 inhibitor
(SB431542) had no effect. Data are plotted as mean ± SEM from
three independent experiments; *p < 0.05, **p < 0.01.robust readout of cardiac function, and investigators were
blinded to treatments during the analysis. A recent system-
atic review of pre-clinical studies showed that the overall
benefit of CDC and other cardiac stem cell treatments
following MI was a small improvement in ejection fraction
comparedwith placebo controls, but improvementwas not
present in all studies (Zwetsloot et al., 2016; Li et al., 2009).
If improved functional outcomes are not reproducible in
a standardized pre-clinicalmodel, translationof anybenefit
to patients becomes even more challenging. Indeed, a
recent meta-analysis of 1,871 individual patient datasets
from 28 studies of acute MI patients found that intracoro-
nary cell therapy provided no beneficial effect on left
ventricular function (Gyongyosi et al., 2015). It is critical,
therefore, that pre-clinical studies are reproducible to help
improve the translatability of pre-clinical findings (Jones
et al., 2015) and to determine the essential factors respon-
sible for beneficial outcomes in cardiac stem cell therapy.
CDCs andMSCs are currently in clinical trials for a range
of cardiac myopathies (Golpanian et al., 2016), and consis-
tency of cell preparation/culture techniques is critical for1294 Stem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017their efficacy. Although endoglin (CD105) is used as a
marker of CDCs, we now show its critical importance for
maintaining their paracrine pro-angiogenic properties.
Furthermore, our findings suggests that if CDCs are
cultured in animal-free media for therapeutic purposes,
addition of BMP9 will help to maintain endoglin expres-
sion and ensure maximal pro-angiogenic paracrine activ-
ities of these cells prior to delivery in cardiac patients.EXPERIMENTAL PROCEDURES
Mouse Models
All animal experiments were approved by the local ethics commit-
tee and performed in accordance with the Animals (Scientific Pro-
cedures) Act 1986 and the EU Directive 2010/63/EU. Floxed Endo-
glinmice and Rosa26-CreERT2mice have been previously described
(Allinson et al., 2007; Anderberg et al., 2013; Mahmoud et al.,
2010). CAG-farnesyl-eGFP mice in which expression of farnesy-
lated EGFP is ubiquitously driven by the CAG promoter were
generated as part of this study (Figure S1). All mice used in this
study were in a C57BL/6 genetic background.
CDC Preparation
CDCs were cultured from CAG-eGFP;Engfl/fl;Rosa26-CreERT2 mouse
hearts using a previously described method (Davis et al., 2009;
Messina et al., 2004). In brief, hearts from mice aged 3–6 weeks
were finely minced and individual heart fragments were plated
onto a fibronectin-coated dish in Iscove’s modified Dulbecco’s
medium (IMDM) containing 20% serum and cultured for approx-
imately 2weeks, allowing explant-derived cells to proliferate out of
the tissue fragments. Bright-phase EDCs were then harvested and
plated on poly-D-lysine-coated plates with cardiosphere growth
medium (65% DMEM/F12, 35% IMDM, 7% fetal bovine serum
[FBS], 2% B27 [Invitrogen], 25 ng/mL cardiotrophin [Peprotech
EC], 10 ng/mL epidermal growth factor [EGF; Peprotech],
20 ng/mL basic fibroblast growth factor [Promega], and 5 units of
thrombin [Sigma]). After 1 week CSps were collected and cultured
in cardiosphere growth medium on fibronectin-coated flasks to
generate CDCs, which were used at P2. Endoglin knockout CDCs
(EngKO) were generated by the addition of 3 mM 4-OHT to the cul-
ture medium for 96 hr at P1, followed by 4 days of culture required
for endogenous endoglin protein turnover with fresh media
changes to allow 4-OHTwashout. Cells were used immediately af-
ter endoglin protein depletion (or equivalent timings for control
cells). In addition, CDCs were prepared from wild-type C57BL/6
mice and treated with 4-OHT over the same time course to deter-
mine the effect of tamoxifen alone.
CDC Characterization and Preparation of
Conditioned Medium
For characterization of surface marker expression, CDCs
were incubated with antibodies against CD90 (553006, BD Bio-
sciences), CD105 (14105185, eBioscience), CD31 (553370, BD
Biosciences), CD45 (11045181, eBioscience), SCA-1 (557405, BD
Biosciences), and cKIT (35117182, eBioscience). Negative staining
for DAPI was used to provide a live/dead cell gate. Cells were
analyzed using an LSRII flow cytometer and FACSDiva software
(BD Biosciences). Positive cells were defined as the percentage
of the cell population stained by more than 99.7% of isotype-
matched antibody.
To prepare CM, we cultured CDCs in serum-free IMDM for 48 hr.
For specific experiments, ALK5 inhibitor (SB431542, Sigma) or
BMP9 (Peprotech) were added to CDCs for 24 hr and washed
awaywith PBS prior to 48 hr of culture in fresh serum-freemedium
to prepare CM. Filtered CMwas stored at80Cprior to use, allow-
ing only one freeze-thaw cycle per aliquot. Protein concentration
was measured by Bradford assay (Bio-Rad).
Endothelial Cell Culture
HUVECs (Promocell) were grown in MV endothelial growth
cell medium (Promocell). Mouse lung endothelial cells (MLECs)
were cultured as previously described (Anderberg et al., 2013)
on 0.1% gelatin-coated flasks in MV2 endothelial growth cell
medium (Promocell). HMEC-1 cells (Ades et al., 1992) were
cultured on 0.1% gelatin-coated flasks in H-medium (MCDB131,
4 mM L-glutamine, 1% penicillin/streptomycin, 1 mg/mL hydro-
cortisone, 10% FBS) with 20 ng/mL EGF.
2D Matrigel Angiogenesis Assay
HMEC-1 cells were cultured on growth factor reduced (GFR)
Matrigel in H-medium without EGF. Either CM or IMDMmedium
was added to H-medium to a final concentration of 20%. Tubule
formation was imaged after 18 hr using an Axiovert200 inverted
microscope fitted with an AxioCamHR digital camera. Total tubule
length was quantified using NeuronJ plugin software.
Spheroid Angiogenesis Assay
HUVECs in MV medium containing 0.25% methylcellulose were
dispensed as 20-mL drops to generate spheroids that were mixed
with fibrinogen (2.5 mg/mL)-aprotinin (4 U/mL, Sigma) mixture
in the presence of thrombin (50 U/mL, Sigma) and spheroids
cultured for 48 hr in MV medium with CM or IMDM added to a
final concentration of 40%. At least 20 spheroids per condition
were photographed using a Nikon ELWD 0.3/OD75 light micro-
scope with Nikon DS-Fi1 digital camera, and length of sprouts
were analyzed using ImageJ software.
Endothelial Cell Proliferation and Viability Assays
Endothelial cell proliferationwasanalyzedusingCyQUANTNFCell
Proliferation Assay Kit (Life Technologies) following the manufac-
turer’s instructions. In brief, HUVECswere cultured inMVmedium
at37Cfor 24or48hr. Subsequently, sampleswere analyzedusinga
fluorometer (Thermo Scientific) at 485-nm excitation and 530-nm
emission, anddata analyzed usingAscent software version 2.5. Cell
viability of HUVECs cultured in CDC-CM for 24 hr and 48 hr was
determined by a colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-di-
phenyl tetrazolium bromide (MTT; Sigma) assay. Absorbance was
measured at 550 nm by MultiSkan (Thermo LabSystems).
Scratch-Wound Healing Assay
HUVECs were plated on a 6-well-plate at a density of 5 3 105 cells
and incubated inMVmediumat 37C for 24 hr. A scratch ‘‘wound’’was made with a 200-mL Gilson pipette tip. Microscope images of
the ‘‘wound’’ areawere takenat0, 24, and48hr and rate of ‘‘wound’’
closure was calculated from the mean of six assays. Images were
takenusing aNikonELWD0.3/OD75 lightmicroscope andaNikon
DS-Fi1 digital camera, and analyzed using ImageJ software.
In Vivo Matrigel Plug Assay
GFR Matrigel (250 mL) was seeded with MLECs and 50 mL of CM
and injected subcutaneously into flanks of adult C57BL/6 mice.
Plugs were harvested after 14 days and cryosections were analyzed
by immunostaining.
Tissue Processing and Staining
Animals were humanely killed and tissue lightly fixed in para-
formaldehyde (0.2%, overnight), equilibrated in 30% sucrose,
and embedded in OCT compound. Cryosections were stained
with anti-CD31 (553370, BD Biosciences), anti-SM22a (ab14106,
Abcam), anti-aSMA (C6198, Sigma), and anti-phospho-histone
H3 (06570, Millipore), and detected with secondary antibodies
conjugated to Alexa 488 or Alexa 568. Sections were mounted
with prolong Gold, imaged using an Axioimager M2 microscope
fittedwithanApotome (Zeiss), andanalyzedusing ImageJ software.
qPCR
RNA was extracted from the left ventricle using a Qiagen RNeasy
Fibrous Tissue Mini Kit (Qiagen) according to the manufacturer’s
instructions. cDNA was prepared using a Tetro cDNA synthesis kit
(Bioline) and Taq polymerase (Applied Biosystems). Commercial
Taqman probes for Eng (Mm00468252_m1), Bmp9 (Mm00807340_
m1), Bmp10 (Mm01183889_m1), Tgfbeta1 (Mm01178820_m1),
Tgfbeta3 (Mm00436960_m1), Gapdh (Mm99999915_g1), and
Hprt1 (Mm00446968_m1) were from Life Technologies and used
for qPCR on a Quantstudio 6&7 Flex Real-Time PCR system. Data
were analyzed using comparative Ct (DDCt) to determine relative
gene expression.
Western Blotting
CDCs were treated with BMP9 (2 ng/mL) or TGFb1 (5 ng/mL) for
30 min before preparing whole-cell protein lysates in SDS sample
buffer. HUVECs were serum starved for 4 hr before addition of
CM and protein lysates prepared. Proteins were separated on 10%
polyacrylamide gels and transferred onto polyvinylidene fluoride
membrane before blocking with 5% powdered milk/TBST (Tris-
buffered saline + Tween 20) and incubated with primary antibody
to detect either phospho-SMAD1/5/8 (9516, Cell Signaling), phos-
pho-SMAD2 (3108, Cell Signaling), phospho-AKTSer473 (4060, Cell
Signaling), phospho-AKTThr308 (13038, Cell Signaling), AKT (4691,
Cell Signaling), phospho-SMAD3 (18801, Epitomics), a-tubulin
(T6199, Sigma), or b-actin (A5316, Sigma). Membranes were incu-
bated with secondary antibody, either anti-rabbit horseradish
peroxidase (HRP) or anti-mouse HRP (Dako) in blocking solution
before detection using SuperSignal Chemiluminescent Substrate,
and densitometric analysis using ImageQuant TL v2005 software.
Myocardial Infarction
AcuteMI was created in adult male C57BL/6mice (12–14 weeks) as
previously described (Redgrave et al., 2016; van Laake et al., 2007).Stem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017 1295
Mice were pre-medicated with fentanyl/fluanisone (Hypnorm;
0.4 mL/kg) to provide intraoperative analgesia and anesthetized
using isoflurane. Anesthesia was maintained using mechanical
ventilation following endotracheal intubation. Left-side thoracot-
omy was performed through the fourth intercostal space and
the left anterior descending coronary artery was ligated with a
7-0 Prolene suture. Occlusion of the vessel was verified by visible
blanching of the myocardium, and only those with large infarcts
progressed to the study.Micewere then subjected to two intramyo-
cardial injections into the infarct border zone with 10 mL of PBS
(MI group) or approximately 53 105 either control CDCs or EngKO
CDCs, with the surgeon blinded to CDC genotype. Mice in the
sham group underwent left-side thoracotomywithout left anterior
descending artery ligation or cell injection.
Cardiac MRI
Cardiac function was monitored after 7 and 28 days using MRI
as previously described (Redgrave et al., 2016; Schneider et al.,
2006). A horizontal bore 7.0T Varian system (Varian) equipped
with a 12-cm microimaging gradient insert (40 gauss/cm) was
used to acquire MR images. Anesthetized mice were positioned
on a custom built sled (Dazai Research Instruments) with inte-
grated electrocardiographic, respiratory, and cutaneous tempera-
ture monitoring. An SA Instruments small animal system was
used for physiological monitoring and gating. A 30-mm quadra-
ture birdcage coil (Rapid Biomedical) was used to transmit/receive
the MR signal. Global cardiac function was measured from
contiguous 1-mm slices covering the whole left ventricle using
an ECG-triggered, respiratory gated gradient echo (FLASH) cine
MR sequence (echo time 1.42 ms, repetition time 5 ms, flip angle
15, matrix 128 3 128, field of view 25.6 mm 3 25.6 mm, and
4 averages). MR images were analyzed by investigators blinded
to mouse treatment using ImageJ (NIH) according to a published
protocol (Schneider et al., 2006).
RT-PCR
RNA was extracted from CDCs using a Qiagen RNeasy Micro Kit
according to the manufacturer’s instructions. cDNA was prepared
using SuperScript III First-Strand Synthesis System (Life Technolo-
gies). Taq polymerase (Applied Biosystems) was used for RT-PCR,
and PCR products were separated on an agarose gel, stained with
ethidium bromide, and visualized with UV light.
ELISA
Mouse serumwas prepared by allowing 1-mL blood samples to clot
for 2 hr in a serum separator tube (BD Biosciences) at room temper-
ature before centrifugation for 15 min at 1500 3 g and collection
of supernatant. ELISAs were performed according to the manufac-
turer’s instructions to detect TGFb1, VEGFA (R&D); and TGFb3,
BMP9, and BMP10 (Cloud-Clone Corporation).
Statistical Analysis
Results are presented as the mean of values ± SEM unless indicated
otherwise. The number of independent experiments for each study
is indicated in the figure legends. The statistical significance of dif-
ferences between the mean of two groups was determined using
Student’s t test. When more than two experimental groups were1296 Stem Cell Reports j Vol. 8 j 1287–1298 j May 9, 2017analyzed, statistical significance of differences was first evaluated
by one-way ANOVA. When multiple experimental groups were
compared at different time points, data were analyzed by two-
way ANOVA and post hoc t tests corrected for multiple compari-
sons using the Holm-Sı´da´k method. Data were analyzed using
GraphPad Prism software and a probability (p) value of less than
0.05 was considered statistically significant.
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